Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.375 EUR | -2.66% | -8.86% | -9.73% |
Jun. 04 | Innate Pharma: positive data in mycosis fungoides | CF |
Jun. 04 | Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.73% | 212M | |
+49.41% | 56.95B | |
+39.38% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
+25.18% | 12.21B | |
-0.08% | 12.15B |
- Stock Market
- Equities
- IPH Stock
- News Innate Pharma
- Innate Pharma Says Trials of Lymphoma Therapy Placed on Partial Clinical Hold After Patient Death